Trial Profile

A first-in-human study of ConvertibleCAR cell therapy

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 04 Nov 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Convertiable CAR-T cell therapies Parker Institute for Cancer Immunotherapy/Xyphos (Primary)
Indications Cancer
Focus Adverse reactions; First in man
Sponsors Xyphos

Most Recent Events

04 Nov 2019 New trial record
24 Oct 2019 According to a Xyphos media release, the company is planning to initiate this study in 2021. VIVEbiotech (CDMO) will supply lentiviral vectors for this trial.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com